IT1219667B - Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico - Google Patents

Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Info

Publication number
IT1219667B
IT1219667B IT48118/88A IT4811888A IT1219667B IT 1219667 B IT1219667 B IT 1219667B IT 48118/88 A IT48118/88 A IT 48118/88A IT 4811888 A IT4811888 A IT 4811888A IT 1219667 B IT1219667 B IT 1219667B
Authority
IT
Italy
Prior art keywords
uridine
balance
alterated
dopaminergic
disorders due
Prior art date
Application number
IT48118/88A
Other languages
English (en)
Other versions
IT8848118A0 (it
Inventor
Vincenzo Politi
Luca Giovanna De
Stazio Giovanni Di
Mario Materazzi
Original Assignee
Polifarma Spa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Polifarma Spa filed Critical Polifarma Spa
Priority to IT48118/88A priority Critical patent/IT1219667B/it
Publication of IT8848118A0 publication Critical patent/IT8848118A0/it
Priority to CA000600276A priority patent/CA1327003C/en
Priority to JP1150354A priority patent/JPH0623109B2/ja
Priority to DE68912419T priority patent/DE68912419T2/de
Priority to EP89830264A priority patent/EP0348360B1/en
Priority to AT89830264T priority patent/ATE100322T1/de
Priority to US07/367,615 priority patent/US4960759A/en
Priority to KR1019890008467A priority patent/KR900000092A/ko
Application granted granted Critical
Publication of IT1219667B publication Critical patent/IT1219667B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/06—Pyrimidine radicals

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
IT48118/88A 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico IT1219667B (it)

Priority Applications (8)

Application Number Priority Date Filing Date Title
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico
CA000600276A CA1327003C (en) 1988-06-21 1989-05-24 Pharmacological use of uridine in the treatment of nervous disorders
JP1150354A JPH0623109B2 (ja) 1988-06-21 1989-06-13 脳神経障害治療用薬剤
DE68912419T DE68912419T2 (de) 1988-06-21 1989-06-14 Verwendung von Uridin zur Behandlung nervöser Störungen.
EP89830264A EP0348360B1 (en) 1988-06-21 1989-06-14 Pharmacological use of uridine in the treatment of nervous disorders
AT89830264T ATE100322T1 (de) 1988-06-21 1989-06-14 Verwendung von uridin zur behandlung nervoeser stoerungen.
US07/367,615 US4960759A (en) 1988-06-21 1989-06-19 Pharmacological use of uridine in the treatment of nervous disorders
KR1019890008467A KR900000092A (ko) 1988-06-21 1989-06-20 신경 장애의 치료에 있어서 유리딘의 약리학적 용도

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Publications (2)

Publication Number Publication Date
IT8848118A0 IT8848118A0 (it) 1988-06-21
IT1219667B true IT1219667B (it) 1990-05-24

Family

ID=11264638

Family Applications (1)

Application Number Title Priority Date Filing Date
IT48118/88A IT1219667B (it) 1988-06-21 1988-06-21 Impiego di uridina nel trattamento farmacologico di disturbi dovuti ad alterato equilibrio dopaminergico

Country Status (8)

Country Link
US (1) US4960759A (it)
EP (1) EP0348360B1 (it)
JP (1) JPH0623109B2 (it)
KR (1) KR900000092A (it)
AT (1) ATE100322T1 (it)
CA (1) CA1327003C (it)
DE (1) DE68912419T2 (it)
IT (1) IT1219667B (it)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2634374B1 (fr) * 1988-07-19 1993-10-15 Laboratoires Serobiologiques Agents photoprotecteurs, cytophotoprotecteurs cutanes ayant une activite photoprotectrice des cellules constitutives, fonctionnelles de la peau, en particulier des cellules de langerhans, a base de composes nucleiques : nucleoprotides, ribonucleotides et desoxyribonucleotides, ribonucleosides et desoxyribonucleosides, compositions cosmetiques ou dermo-pharmaceutiques contenant un tel agent ainsi que des nouveaux composes en soi
WO1994026280A1 (fr) * 1993-05-19 1994-11-24 Korea Green Cross Corporation Remede contre l'arthrite contenant de l'uridine comme ingredient actif
US5962459A (en) * 1996-05-28 1999-10-05 Polifarma S.P.A. Therapeutic active agent for treatment of neuron degenerative diseases
IT1290781B1 (it) * 1996-05-28 1998-12-10 Polifarma Spa Agente attivo terapeutico per il trattamento di malattie degenerative neuronali.
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US8143234B2 (en) 1998-07-31 2012-03-27 Massachusetts Institute Of Technology Uridine administration improves phosphatide synthesis, synaptic transmission and cognitive function
US8314064B2 (en) 1998-07-31 2012-11-20 Massachusetts Institute Of Technology Uridine administration stimulates membrane production
US20070004670A1 (en) * 1998-07-31 2007-01-04 Richard Wurtman Compositions containing citicoline, and methods of use thereof
US20050203053A1 (en) * 1999-07-30 2005-09-15 Wurtman Richard J. Uridine administration improves phosphatide synthesis, synaptic transmission and cogntive function
ATE374029T1 (de) 1998-07-31 2007-10-15 Massachusetts Inst Technology Behandlung der alzheimer-krankheit durch erhöhung des cytidin-spiegels in vivo
US8518882B2 (en) 1998-07-31 2013-08-27 Massachusetts Institute Of Technology Methods and compositions for ameliorating or inhibiting decline in memory or intelligence or improving same
US20060069061A1 (en) * 1998-07-31 2006-03-30 Dick Wurtman Compositions containing uridine and choline, and methods utilizing same
US6472378B2 (en) 1998-08-31 2002-10-29 Pro-Neuron, Inc. Compositions and methods for treatment of mitochondrial diseases
US7807654B2 (en) 1998-08-31 2010-10-05 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
US7915233B1 (en) 1998-08-31 2011-03-29 Wellstat Therapeutics Corporation Compositions and methods for treatment of mitochondrial diseases
NZ513926A (en) 1999-02-23 2001-09-28 Univ California Methods of treatment of mitochondrial disorders
WO2001068104A1 (en) * 2000-03-16 2001-09-20 The Mclean Hospital Corporation Compounds for the treatment of psychiatric or substance abuse disorders
US6727231B1 (en) 2000-10-12 2004-04-27 Repligen Corporation Uridine therapy for patients with elevated purine levels
AUPR951101A0 (en) 2001-12-13 2002-01-24 Centre For Molecular Biology And Medicine Method of treatment
JP2007508315A (ja) * 2003-10-08 2007-04-05 ザ マクレーン ホスピタル コーポレーション ω−３脂肪酸を含む組み合わせを用いて、精神障害、物質乱用障害、および他の障害を治療する方法
CA2566612C (en) * 2004-05-13 2015-06-30 Massachusetts Institute Of Technology Uridine effects on dopamine release
WO2007060886A1 (ja) * 2005-11-24 2007-05-31 National University Corporation Hokkaido University 神経変性疾患治療薬
EP1897937A1 (en) * 2006-09-07 2008-03-12 NeuroProgen GmbH Leipzig Method of culturing NPCs
EP2217075A4 (en) 2007-11-02 2012-01-25 Massachusetts Inst Technology URIDINE FOOD ADDITIONAL AGREEMENT PROCESS AND USE THEREOF
US20100041621A1 (en) * 2008-08-15 2010-02-18 Perry Renshaw Methods and compositions for improving cognitive performance
KR20120103557A (ko) * 2009-07-31 2012-09-19 클레라 아이엔씨. 파킨슨씨병 치료용 조성물 및 치료방법

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1178044B (it) * 1984-10-09 1987-09-03 Polifarma Spa Agente attivo farmaceutico per il trattamento di patologie cerebrali a base di uridina
JPH0669953B2 (ja) * 1985-08-16 1994-09-07 日産化学工業株式会社 脳脊髄系神経栄養剤
DE3883374T2 (de) * 1987-10-28 1993-12-09 Pro Neuron Inc Acylatiertes uridin und cytidin und deren verwendungen.

Also Published As

Publication number Publication date
KR900000092A (ko) 1990-01-30
ATE100322T1 (de) 1994-02-15
US4960759A (en) 1990-10-02
JPH0245425A (ja) 1990-02-15
DE68912419D1 (de) 1994-03-03
EP0348360A3 (en) 1991-10-23
EP0348360B1 (en) 1994-01-19
CA1327003C (en) 1994-02-15
JPH0623109B2 (ja) 1994-03-30
EP0348360A2 (en) 1989-12-27
IT8848118A0 (it) 1988-06-21
DE68912419T2 (de) 1994-08-04

Similar Documents

Publication Publication Date Title
EP0348360A3 (en) Pharmacological use of uridine in the treatment of nervous disorders
NL970006I1 (nl) Gebruik van indolon-derivaten voor het bereiden van geneesmiddelen ter behandeling van de ziekte vanParkinson.
DE3779500D1 (de) Levodopa-methyl-ester enthaltende pharmazeutische zusammensetzungen, ihre herstellung und therapeutische verwendungen.
DK0431580T3 (da) Substituerede cyclohexanoler med virkning på centralnervesystemet
LU91894I2 (fr) 4-aminopyridine et ses dérivés
NL300140I1 (nl) Galanthamine, of verbindingen die eraan analoog zijn, voor behandeling van de ziekte van Alzheimer.
EP0594607A4 (en) Enhancement of the down-regulation of autoimmune diseases by oral administration of autoantigens.
DE69112895D1 (de) Pharmazeutische Verbindungen.
EP1014996A4 (en) PREPARATION OF SACCHARIDES AND METHODS FOR TREATING ALZHEIMER'S DISEASE AND OTHER AMYLOIDOSES
ES2037208T3 (es) Un metodo para preparar derivados 3-aminometilicos de indano, indolina, dihidrobenzofurano y dihidrobenzotiofeno.
BR0207802A (pt) Uso de agonistas inversos de gabaa em combinação com agonistas parciais do receptor de nicotina, estrogênios, moduladores de estrogênio seletivos, ou vitamina e para o tratamento de distúrbios cognitivos
EP0616032A3 (en) Preventive or therapeutic agents against Alzheimer's disease, a screening method and the human tau kinase protein.
ES2141787T3 (es) Derivados de la 1,2,3,4-tetrahidro-9-acridinamina.
FI113767B (fi) Bentsimidatsolijohdannaisia, joilla on dopaminergistä vaikutusta keskushermostossa
ES2136167T3 (es) Composiciones de idebenona para tratar la enfermedad de alzheimer.
MX9306049A (es) Dinucleotido de nicotinamida-ademina y fosfato de dinucleotido de nicotinamida-adenina como farmacos para tratar la enfermedad de alzheimer.
DE69928521D1 (de) Cabergolin und pramipexol zur behandlung von krankheiten des zentralnervensystems, insbesondere parkinsonscher krankheit
DE68927055D1 (de) 2',5'-oligoadenylat-derivate zur verwendung als heilmittel
EP0486584A4 (en) Dopaminergic neurotrophic factor for treatment of parkinson's disease
HUP9701606A2 (hu) Szulbutiamin alkalmazása bizonyos pszichomotoros és pszichointellektuális rendellenességek kezelésére használható gyógyszerkészítmények előállítására
JPS57167922A (en) Psychotropic drug
MY103584A (en) 8(alpha)-acylaminoergoline, its preparation and pharmaceutical compositions containing it
MX9206635A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
MX9302225A (es) Cicloalquenos y cicloalcanos 1,3-substituidos como agentes del sistema nervioso central.
EP0402733A3 (de) Mittel zur Behandlung von Erkrankungen des Zentralnervensystems und zur Förderung der cerebralen Durchblutung

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19960621